For the Inventor, By the Inventor

Enter assignee name

Constance, Germany

Takeda Gmbh

USPTO Granted Patents = 47

CIPO Patents = 6

EPO Patents = 30

Trademarks = 12

Forward Citations = 207

Loading Chart...

Loading Chart...

119 inventors (with patents filed for the assignee):

Beate Schmidt (10 out of 29 patents)

Ulrich Kautz (8 out of 21 patents)

Degenhard Marx (8 out of 15 patents)

4. Torsten Dunkern (6 out of 6 patents)

5. Christof Zitt (6 out of 9 patents)

6. Armin Hatzelmann (6 out of 20 patents)

7. Rango Dietrich (5 out of 30 patents)

8. Hans-Peter Kley (5 out of 17 patents)

9. Guido Hanauer (4 out of 6 patents)

10. Hartmut Ney (4 out of 12 patents)

11. Geert Jan Sterk (4 out of 28 patents)

12. Josef Stadlwieser (4 out of 8 patents)

13. Heiko Bernsmann (4 out of 4 patents)

14. Andreas Pahl (4 out of 9 patents)

15. Rolf-Peter Hummel (4 out of 12 patents)

Core Competencies:

Idiopathic Pulmonary Fibrosis

Nonalcoholic Fatty Liver Disease

GM-CSF Neutralizing Compound

PDE4 Inhibitors

Roflumilast

Ciclesonide

Pulmonary Hypertension

Diabetes Mellitus Type 2

Aerosolization Apparatus

Lyophilized Formulation

Human G-Protein Coupled Receptor

47 patents: Sort by Forward Citations

1. 11690839 - Treatment of idiopathic pulmonary fibrosis (2023-07-04),

2. 11179384 - Treatment of nonalcoholic fatty liver disease (2021-11-23),

3. 11173208 - Liquid formulation comprising GM-CSF neutralizing compound (2021-11-16),

4. 10758621 - Liquid formulation comprising GM-CSF neutralizing compound (2020-09-01),

5. 10745475 - Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics (2020-08-18),

6. 10495630 - Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions (2019-12-03),

7. 9962377 - Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors (2018-05-08),

8. 9919051 - Liquid formulation comprising GM-CSF neutralizing compound (2018-03-20),

9. 9833410 - Lyophilized formulation comprising GM-CSF neutralizing compound (2017-12-05),

10. 9545490 - Apparatus for the aerosolization of large volumes of dry powder (2017-01-17),

11. 9422327 - Process for preparing crystalline ciclesonide with defined particle size (2016-08-23),

12. 9387205 - Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors (2016-07-12),

13. 9376442 - Methylpyrrolopyrimidinecarboxamides (2016-06-28),

14. 9340522 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2016-05-17),

15. 9309187 - EP2 receptor agonists (2016-04-12),

Takeda GmbH is a global pharmaceutical company that specializes in innovative medicines. With a focus on research and development, Takeda aims to improve patient health and provide treatments for various medical conditions. Their dedication to scientific excellence and patient-centric approach has established Takeda as a leading pharmaceutical company worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

47 Patents

#4 in Constance

#1,158 in Germany

#14,403 in the World

Constance, Germany

Takeda Gmbh

Forward Citations = 207

119 inventors:

Beate Schmidt (10 out of 29 patents)

Ulrich Kautz (8 out of 21 patents)

Degenhard Marx (8 out of 15 patents)

4. Torsten Dunkern (6 out of 6 patents)

5. Christof Zitt (6 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…